Abstract
Most humans have been infected by Cytomegalovirus (CMV) by the time they reach forty years of age. Whereas most of these CMV infections are well controlled by the immune system, congenital infection can lead to serious health effects and death for the fetus and neonate. With clear evidence that risk to the fetus is lower during chronic maternal infection, and varies in association with gestational age at the time of primary maternal infection, further research on humoral immune responses to primary CMV infection during pregnancy is needed. Here, systems serology tools were applied to characterize antibody responses to CMV infection among pregnant and non-pregnant women experiencing either primary or chronic infection. Whereas strikingly different antibody profiles were observed depending on infection status, more limited differences were associated with pregnancy status. Beyond known differences in IgM responses that are used clinically for identification of primary infection, distinctions observed in IgA and FcγR binding antibody responses and among viral antigen specificities accurately predicted infection status in a cross-sectional cohort. Leveraging machine learning, longitudinal samples were also used to define an immunological clock of CMV infection from primary to chronic states and predict time since primary infection with high accuracy. Humoral responses diverged over time in an antigen-specific manner, with IgG3 responses toward tegument decreasing over time as is typical of viral infections, while those directed to pentamer and glycoprotein B were lower during acute and greatest during chronic infection. In sum, this work provides new insights into the antibody response associated with CMV infection status in the context of pregnancy, revealing aspects of humoral immunity that have the potential to improve CMV diagnostics and to support clinical trials of interventions to reduce mother-to-fetus transmission of CMV.
Competing Interest Statement
A patent application for Systems and methods for identifying and treating primary and latent infections and/or determining time since infection, WO2023154857A2, has been submitted by A.P.H, D. L., A.M, and M.E.A..
Funding Statement
This study was supported in part by Infect-ERA, GSK and Sanofi via the CYMAF consortium, as well as by NIH U19AI145825. Pentamer and gB proteins were provided by GSK. A.M. is Research Director at the F.R.S., FNRS, Belgium.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Fondazione IRCCS Policlinico San Matteo gave ethical approval for this work. IRB of Erasme Hopital gave ethical approval for this work. IRB of Dartmouth College gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data used in the study will be made available as Supplemental Data File 1 upon publication in peer-reviewed forum.
